

**SUPPLEMENTAL MATERIAL****Cardiac mortality among 200,000 five-year survivors of cancer diagnosed aged 15-39 years: The Teenage and Young Adult Cancer Survivor Study**

Henson, Cardiac mortality among teenagers and young adults

Katherine E Henson DPhil <sup>1,2</sup>, Raoul C Reulen PhD <sup>2</sup>, David L Winter HNC <sup>2</sup>,  
Chloe J Bright MSc <sup>2</sup>, Miranda M Fidler PhD <sup>2</sup>, Clare Frobisher PhD <sup>2</sup>,  
Joyeeta Guha PhD <sup>2</sup>, Kwok F Wong PhD <sup>2</sup>, Julie Kelly <sup>2</sup>, Angela B Edgar MD <sup>3</sup>,  
Martin G McCabe MD PhD <sup>4</sup>, Jeremy Whelan MD MBBS <sup>5</sup>, David J Cutter DPhil <sup>1, 6</sup>,  
Sarah C Darby PhD <sup>1, 6</sup>, Mike M Hawkins DPhil <sup>2</sup>

<sup>1</sup> Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Oxford

<sup>2</sup> Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, Public Health Building, University of Birmingham, Edgbaston, Birmingham

<sup>3</sup> Department of Paediatric Haematology and Oncology, Royal Hospital for Sick Children, University of Edinburgh, Edinburgh EH9 1LF

<sup>4</sup> Institute of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre

<sup>5</sup> National Institute for Health Research University College London Hospitals Biomedical Research Centre, London

<sup>6</sup> British Heart Foundation Centre for Research Excellence

Corresponding author: Professor Mike Hawkins

Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, Public Health Building, University of Birmingham, Birmingham, B15 2TT;

+44 (0)121 414 7924; [m.m.hawkins@bham.ac.uk](mailto:m.m.hawkins@bham.ac.uk)

Disclaimers: All authors declare that they have no conflicts of interest in relation to this work.

Key words: adolescent, cardiac deaths, epidemiology, heart diseases, mortality, neoplasms

**Supplemental Table 1: First Primary Cancer Classification Detail –Modified from Birch et al**

1

<b>First Primary Cancer Grouping</b>	<b>Specific Cancer Description</b>
Breast	Breast
	Germ cell gonadal
	Other specified gonadal tumours
Testicular	Testicular
Cervix	Cervix
Melanoma	Melanoma & Naevi
	Pilocytic astrocytoma
	Other specified astrocytoma
	Glioblastoma/anaplastic astrocytoma
	Astrocytoma NOS *
	Oligodendroglioma
	Other specified glioma
	Glioma, NOS
	Ependymoma
	Medulloblastoma
	Supratentorial PNET
	Craniopharyngioma
	Other Pituitary tumours
	Pineal tumours
	Choroid plexus tumours
	Meningioma
	CNS nerve sheath tumours
	Other specified CNS †
	Unspecified malignant CNS
	Unspecified benign CNS
Central Nervous System Tumours	Other CNS
	Germ cell intracranial
	Hodgkin Disease (specified)
Hodgkin	Hodgkin Disease NOS
	Specified NHL ‡
	Unspecified NHL
Non-Hodgkin Lymphoma	Misc lymphoreticular neops NEC
Thyroid	Thyroid
	Colon & rectum
	Stomach
	Liver
	Pancreas
Gastrointestinal	Gastrointestinal tract (other)
	Fibrosarcoma
	Malig fibrous histiocytoma
	Dermatofibrosarcoma
	Rhabdomyosarcoma
	Liposarcoma
	Leiomyosarcoma
	Synovial sarcoma
	Clear cell sarcoma
	Blood vessel tumours
	Nerve sheath tumours
	Alveolar soft part sarcoma
	Other Specified Soft Tissue Sarcoma
Soft Tissue Sarcoma	Unspecified Soft Tissue Sarcoma
	Ovary
	Germ cell gonadal (if female)
Ovary	Other specified gonadal tumours(if female)
	Bladder
Bladder	Other bladder
	GU tract §
	Kidney
Kidney and GU tract §	GU tract (other)

	Wilms tumour
	Nasopharyngeal
Head & Neck	Other lip/oral cavity/pharynx
	Other Nasal cavity/middle ear
	Acute Lymphoid Leukaemia
	Chronic Myeloid Leukaemia
	Other Lymphoid Leukaemia
	Other Myeloid Leukaemia
Leukaemia (excl. AML <sup>  </sup> )	Other Specified Leukaemia
	Other Unspecified Leukaemia
	Osteosarcoma
	Chondrosarcoma
	Ewing sarcoma
	Ewing sarcoma NOT bone
	Ewing sarcoma site unspecified
	Other bone tumours specific
Bone Tumour	Bone tumours unspecified
Acute Myeloid Leukaemia	Acute Myeloid Leukaemia
Lung	Trachea, bronchus & lung

\* NOS = not otherwise specified

† CNS = central nervous system

‡ NHL = non-Hodgkin lymphoma

§ GU = genitourinary

|| AML = acute myeloid leukaemia

**Supplemental Table 2: Cardiac disease classification: ICD revision 9 and ICD revision 10**

<b>Cause of Death</b>	<b>ICD<sup>*</sup>-9</b>	<b>ICD<sup>*</sup>-10</b>
<b>All cardiac disease</b>	<b>391, 392.0, 393-398, 402, 404, 410-414, 416, 420-429</b>	<b>I01, I02.0, I05-I09, I11, I13, I20-I25, I27.1-I27-9, I30-I52</b>
Cardiomyopathy/ congestive heart failure	391.2, 398.0, 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 422, 425, 428, 429.0, 429.1, 429.3	I01.2, I09.0, I11.0, I13.0, I13.2, I40-I43, I50, I51.4-5, I51.7
Valvular heart disease	424	I34-I39
Rheumatic valvular heart disease	391.1, 394-397	I01.1, I05-I08, I09.1
Ischaemic heart disease	410-414, 429.7	I20-I25
Arrhythmias	426-427	I44-49
Pericardial disease	391.0, 393, 420, 423	I01.0, I09.2, I30-I32

\* ICD = International Classification of Diseases

**Supplemental Table 3: Relative risks (RR) and excess mortality ratios (EMR) relating to age at cancer diagnosis and first primary cancer type from a multivariable Poisson regression model adjusted for the specified potential confounders <sup>\*\*</sup>,<sup>††</sup> (corresponding to Table 2 and Table 3)**

Multivariable model		All cardiac disease		Ischaemic Heart Disease		Valvular HD		Cardiomyopathy / CHF *	
		RR <sup>†</sup> (95% CI <sup>‡</sup> )	EMR <sup>§</sup> (95% CI)	RR (95% CI)	EMR (95% CI)	RR(95% CI)	EMR (95% CI)	RR (95% CI)	EMR (95% CI)
<b>Age at Cancer Diagnosis <sup>**</sup></b>	15-19	(ref) <sup>  </sup>		(ref)		(ref)		(ref)	
	20-24	0.7 (0.5,0.9)	0.8 (0.5,1.1)	0.8 (0.6,1.1)	1.2 (0.8,2.0)	0.5 (0.2,1.1)	0.5 (0.2,1.2)	0.7 (0.4,1.4)	0.7 (0.2,2.3)
	25-29	0.6 (0.4,0.7)	0.7 (0.5,1.0)	0.7 (0.5,0.9)	1.1 (0.7,1.9)	0.3 (0.1,0.7)	0.3 (0.1,0.7)	0.7 (0.4,1.4)	0.6 (0.2,1.9)
	30-34	0.5 (0.4,0.6)	0.6 (0.4,0.9)	0.6 (0.4,0.8)	1.1 (0.6,1.9)	0.2 (0.1,0.4)	0.4 (0.0,0.2)	0.9 (0.5,1.6)	1.3 (0.4,3.6)
	35-39	0.5 (0.4,0.6)	0.6 (0.4,0.9)	0.6 (0.4,0.8)	1.2 (0.7,2.2)	0.1 (0.1,0.3)	0.2 (0.0,0.4)	0.8 (0.4,1.5)	0.8 (0.3,2.6)
	<i>2p for trend:</i>	<0.0001	0.02	0.001	0.67	<0.0001	<0.0001	0.85	0.76
<b>First Primary Cancer <sup>††</sup></b>	Breast	0.3 (0.2,0.3)	0.1 (0.0,0.2)	0.3 (0.2,0.4)	0.1 (0.1,0.2)	0.1 (0.1,0.3)	##	0.2 (0.1,0.4)	0.0 (0.0,0.5)
	Testicular	0.3 (0.3,0.4)	0.0 (0.0,0.5)	0.3 (0.3,0.4)	##	0.3 (0.1,0.6)	0.2 (0.09,0.6)	0.4 (0.2,0.6)	##
	Cervix	0.3 (0.2,0.3)	0.06 (0.0,0.2)	0.3 (0.3,0.4)	0.1 (0.1,0.2)	0.1 (0.1,0.3)	##	0.2 (0.1,0.3)	##
	Melanoma	0.1 (0.1,0.2)	##	0.1 (0.1,0.2)	##	0.1 (0.0,0.2)	##	0.2 (0.1,0.4)	##
	Central Nervous System Tumours	0.4 (0.3,0.4)	0.1 (0.1,0.3)	0.4 (0.3,0.5)	0.1 (0.1,0.3)	0.2 (0.1,0.5)	0.1 (0.0,0.5)	0.4 (0.2,0.7)	0.2 (0.1,0.7)
	Hodgkin	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)
	Non-Hodgkin Lymphoma	0.5 (0.4,0.6)	0.3 (0.2,0.5)	0.5 (0.4,0.6)	0.3 (0.2,0.5)	0.2 (0.1,0.7)	0.2 (0.0,0.8)	0.8 (0.5,1.4)	0.6 (0.2,1.5)
	Thyroid	0.2 (0.2,0.3)	0.0 (0.0,0.4)	0.2 (0.2,0.3)	##	0.2 (0.1,0.7)	0.2 (0.0,0.9)	0.3 (0.1,0.7)	0.1 (0.0,1.2)
	Gastrointestinal	0.3 (0.2,0.3)	##	0.3 (0.2,0.4)	##	0.2 (0.1,0.5)	-	0.4 (0.2,0.9)	##
	Soft Tissue Sarcoma	0.3 (0.2,0.4)	0.1 (0.0,0.3)	0.3 (0.2,0.4)	##	0.1 (0.0,0.5)	0.1 (0.0,0.8)	0.8 (0.4,1.5)	0.7 (0.3,1.8)
	Ovary	0.2 (0.1,0.3)	##	0.2 (0.1,0.3)	##	0.1 (0.0,0.6)	-	0.4 (0.2,1.0)	0.2 (0.0,1.2)
	Bladder	0.3 (0.3,0.4)	0.0 (0.0,0.4)	0.3 (0.3,0.4)	##	0.2 (0.1,0.6)	0.1 (0.0,3.4)	0.2 (0.1,0.6)	0.1 (0.0,2.3)
	Kidney and GU tract <sup>#</sup>	0.6 (0.4,0.7)	0.5 (0.3,0.8)	0.6 (0.5,0.8)	0.6 (0.4,0.9)	0.4 (0.1,1.0)	0.3 (0.1,1.4)	0.5 (0.2,1.0)	0.3 (0.1,1.3)
	Head & Neck	0.3 (0.3,0.5)	0.1 (0.0,0.6)	0.4 (0.3,0.5)	0.0 (0.0,546.3)	0.1 (0.0,0.7)	0.0 (0.0,484.6)	0.3 (0.1,0.9)	0.2 (0.0,1.7)
	Leukaemia (excl. AML) <sup>###</sup>	0.4 (0.3,0.6)	0.2 (0.1,0.6)	0.4 (0.3,0.7)	0.2 (0.1,0.7)	##	##	0.5 (0.1,1.5)	0.3 (0.0,3.0)
	Other	0.4 (0.3,0.6)	0.2 (0.1,0.5)	0.4 (0.3,0.6)	0.2 (0.1,0.6)	0.2 (0.1,1.0)	0.2 (0.0,1.3)	0.5 (0.2,1.4)	0.5 (0.1,2.0)
	Bone Tumour	0.3 (0.2,0.5)	0.1 (0.0,0.6)	0.3 (0.2,0.6)	0.1 (0.0,1.1)	0.2 (0.0,1.5)	##	0.4 (0.1,1.6)	0.1 (0.0,78.2)
	Acute Myeloid Leukaemia	0.7 (0.4,1.1)	0.5 (0.2,1.2)	0.5 (0.2,1.0)	0.3 (0.0,1.5)	0.6 (0.1,4.5)	0.6 (0.1,6.1)	2.1 (0.9,4.9)	1.9 (0.7,5.6)
	Lung	0.5 (0.4,0.8)	0.5 (0.3,1.0)	0.5 (0.4,0.8)	0.4 (0.2,1.1)	0.5 (0.1,2.3)	0.7 (0.1,3.3)	0.9 (0.3,2.5)	1.1 (0.3,4.2)
	<i>2p for heterogeneity:</i>	<0.0001	##	<0.0001	##	<0.0001	##	<0.0001	##

\* CHF = congestive heart failure

† RR = relative risks – can be interpreted as ratios of standardised mortality ratios adjusted for confounding risk factors included in the model

‡ CI = confidence interval

§ EMR = excess mortality ratio - can be interpreted as ratios of absolute excess risks adjusted for confounding risk factors included in the model

|| ref = reference group

# GU = genitourinary

## AML = acute myeloid leukaemia

\*\* adjusted for gender, decade of cancer diagnosis, first primary cancer type and attained age

†† adjusted for gender, age at cancer diagnosis, decade of cancer diagnosis and attained age

‡‡ unreliable model fit due to small numbers of events

**Supplemental Table 4: Relative risks (RR) and excess mortality ratios (EMR) after specific cancers in relation to gender, age at cancer diagnosis, decade of cancer diagnosis and attained age from a multivariable Poisson regression model adjusted for the specified confounders <sup>##,\*\*,††,‡‡</sup> (corresponding to Table 4)**

Multivariable model	Hodgkin lymphoma		Non-Hodgkin lymphoma		Central Nervous System Tumours		Cervical Cancer		Breast cancer	
	RR <sup>*</sup> (95% CI <sup>†</sup> )	EMR <sup>‡</sup> (95% CI)	RR (95% CI)	EMR (95% CI)	RR (95% CI)	EMR (95% CI)	RR (95% CI)	EMR (95% CI)	RR (95% CI)	EMR (95% CI)
<b>Gender <sup>##</sup></b>										
Male	(ref) <sup>§</sup>	(ref)	(ref)	(ref)	(ref)	(ref)	-	-	-	-
Female	1.7 (1.4,2.1)	0.5 (0.4,0.7)	1.8 (1.2,2.7)	0.9 (0.4,1.9)	1.3 (0.9,1.9)	0.5 (0.2,1.5)	-	-	-	-
<i>2p for het</i>	<0.0001	<0.0001	0.007	0.74	0.11	0.21	-	-	-	-
<b>Age at Cancer Diagnosis <sup>**</sup></b>										
15-19	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)	-	-	-	-
20-24	0.6 (0.4,0.8)	0.7 (0.5,1.0)	2.3 (0.5,10.8)	#	0.9 (0.3,2.5)	0.8 (0.0,13.2)	-	-	(ref)	(ref)
25-29	0.4 (0.3,0.5)	0.5 (0.3,0.7)	1.9 (0.4,8.5)	#	1.2 (0.5,3.0)	3.2 (0.5,22.9)	(ref)	(ref)	0.4 (0.1,1.4)	0.4 (0.1,2.2)
30-34	0.3 (0.2,0.5)	0.5 (0.3,0.8)	2.2 (0.5,9.3)	#	0.8 (0.3,2.1)	1.3 (0.1,25.0)	1.9 (1.0,3.6)	#	0.3 (0.1,1.0)	0.1 (0.0,1.0)
35-39	0.3 (0.2,0.4)	0.6 (0.4,0.9)	1.5 (0.3,6.5)	#	1.0 (0.4,2.5)	3.2 (0.2,43.2)	1.7 (0.9,3.4)	#	0.3 (0.1,0.8)	0.1 (0.0,0.8)
<i>2p for trend</i>	<0.0001	0.01	0.40	#	0.89	0.25	0.30	#	0.08	0.06
<b>Decade of Cancer Diagnosis <sup>††</sup></b>										
1970-79	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)
1980-89	0.7 (0.6,0.9)	0.4 (0.3,0.6)	1.0 (0.6,1.5)	0.5 (0.2,1.5)	1.3 (0.9,1.9)	2.3 (0.3,18.9)	1.0 (0.7,1.4)	1.2 (0.2,7.1)	1.5 (1.1,2.0)	1.9 (0.5,6.8)
1990-99	0.8 (0.6,1.1)	0.4 (0.2,0.6)	1.2 (0.7,2.0)	0.7 (0.3,1.9)	1.3 (0.8,2.2)	1.4 (0.1,14.4)	0.8 (0.5,1.5)	0.4 (0.0,4.4)	0.9 (0.5,1.4)	#
2000+	1.1 (0.6,2.1)	0.4 (0.2,0.9)	0.6 (0.2,1.9)	0.1 (0.0,2.8)	1.3 (0.5,3.3)	1.3 (0.1,18.5)	0.6 (0.1,2.4)	#	0.6 (0.2,1.6)	0.2 (0.0,37.8)
<i>2p for trend</i>	0.11	<0.0001	0.95	0.15	0.27	0.93	0.48	#	0.87	#
<b>Attained Age <sup>‡‡</sup></b>										
20-39	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)
40-49	1.0 (0.7,1.3)	3.6 (2.4,5.5)	0.8 (0.4,1.7)	2.2 (0.6,7.6)	0.5 (0.3,1.0)	0.7 (0.1,4.3)	0.5 (0.2,1.4)	0.8 (0.1,5.0)	0.6 (0.2,1.7)	2.1 (0.3,14.7)
50-59	0.9 (0.6,1.2)	6.6 (4.2,10.3)	0.6 (0.2,1.2)	1.9 (0.4,9.1)	0.5 (0.3,1.0)	1.4 (0.2,9.4)	0.4 (0.2,1.1)	0.8 (0.1,6.5)	0.4 (0.2,1.2)	0.3 (0.0,245.4)
60+	0.8 (0.6,1.2)	12.5 (7.4,21.1)	0.6 (0.2,1.4)	6.4 (1.4,29.6)	0.4 (0.2,0.9)	1.6 (0.1,25.5)	0.4 (0.1,1.0)	1.1 (0.1,17.7)	0.5 (0.2,1.3)	5.4 (0.6,46.4)
<i>2p for trend</i>	0.24	<0.0001	0.19	0.05	0.11	0.56	0.08	0.99	0.20	0.58

\* RR = relative risks – can be interpreted as ratios of standardised mortality ratios adjusted for confounding risk factors included in the model

† CI = confidence interval

‡ EMR = excess mortality ratio – can be interpreted as ratios of absolute excess risks adjusted for confounding risk factors included in the model

§ ref = reference group

# unreliable model fit due to small numbers of events

## adjusted for age at cancer diagnosis, decade of cancer diagnosis, first primary cancer type and attained age

\*\* adjusted for gender, decade of cancer diagnosis, first primary cancer type and attained age

†† adjusted for gender, age at cancer diagnosis, first primary cancer type and attained age

‡‡ adjusted for gender, age at cancer diagnosis, decade of cancer diagnosis and first primary cancer type

**Supplemental Table 5: Total excess cardiac deaths as a proportion of total excess deaths for all cancers combined and specific first primary cancers subdivided by attained age**

	AER * cardiac / AER all causes (%) by attained age								Total AER (%)	
	20-39		40-49		50-59		60+			
Hodgkin Lymphoma	3.9/75.9	(5.2%)	12.0/75.3	(15.9%)	24.9/118/3	(21.0%)	52.8/191.9	(27.5%)	12.9/89.0	(14.5%)
Non-Hodgkin Lymphoma	1.6/76.6	(2.1%)	4.2/130.8	(3.2%)	5.0/105.6	(4.7%)	14.4/101.5	(14.2%)	4.4/107.2	(4.1%)
Central Nervous System Tumours	1.3/181.8	(0.7%)	1.2/162.2	(0.8%)	2.6/95.8	(2.7%)	0.7/83.5	(0.8%)	1.5/150.4	(1.0%)
Cervical Cancer	0.4/38.9	(1.0%)	0.6/37.0	(1.5%)	1.0/33.8	(3.0%)	2.1/65.6	(3.1%)	0.8/39.7	(2.1%)
Breast Cancer	1.2/359.6	(0.3%)	0.7/258.5	(0.3%)	0.5/130.4	(0.3%)	2.4/86.4	(2.8%)	0.9/205.8	(0.4%)
<b>All Cancers Combined</b>	<b>1.3/91.5</b>	<b>(1.4%)</b>	<b>1.9/103.5</b>	<b>(1.8%)</b>	<b>2.2/67.1</b>	<b>(3.3%)</b>	<b>2.9/66.8</b>	<b>(4.3%)</b>	<b>1.9/88.3</b>	<b>(2.2%)</b>

\* AER = absolute excess risk

**Supplemental Reference**

1. Birch JM, Alston RD, Kelsey AM, Quinn MJ, Babb P, McNally RJQ. Classification and incidence of cancers in adolescents and young adults in England 1979-1997. *Br J Cancer*. 2002; 87: 1267-74.